PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE: In Lung and Heart Transplant Recipients: 1

JJ Egan, J Lomax, L Barber, SS Lok… - …, 1998 - journals.lww.com
Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus
(CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive …

Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection

CV Paya, PE Hermans, TF Smith, J Rakela… - …, 1988 - journals.lww.com
MATERIALS AND METHODS Seventeen patients–12 who had received orthotopic liver
transplants and 5 who had orthotopic kidney transplants at our institution–received …

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

I Johansson, G Mårtensson, U Nyström, S Nasic… - BMC infectious …, 2013 - Springer
Background Cytomegalovirus (CMV) is the most common opportunistic infection following
lung transplantation. CMV replication in the lung allograft is described as accelerating the …

Cytomegalovirus Infedion and Pneumonitis

NA Ettinger, TC Bailey, EP Trulock… - American Review of …, 1993 - atsjournals.org
Using aggressive surveillance of blood, bronchoalveolar lavage (BAL) fluid, and lung tissue,
we sought to determine the incidence of cytomegalovirus (CMV) pneumonitis in isolated …

Prevention and treatment of cytomegalovirus disease in heart transplant patients

RH Rubin - The Journal of heart and lung transplantation, 2000 - Elsevier
Cytomegalovirus (CMV) remains the most important infection affecting heart-transplant
recipients. Treatment of clinical disease is with a two to three–week course of intravenous …

Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation

B Ghassemieh, VN Ahya, MA Baz, VG Valentine… - The Journal of Heart and …, 2013 - Elsevier
BACKGROUND: Cytomegalovirus (CMV) is the most common opportunistic infection in lung
transplantation. A recent multicenter, randomized trial (the AIRSAC study) comparing …

DEVELOPMENT OF GANCICLOVIR RESISTANCE DURING TREATMENT OF PRIMARY CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION1

HR Rosen, KG Benner, KD Flora, JM Rabkin… - …, 1997 - journals.lww.com
Despite recent advances in diagnosis and treatment, cytomegalovirus (CMV*) continues to
be a common cause of infection and disease in solid organ transplant recipients. Risk factor …

[HTML][HTML] Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

L Cherrier, A Nasar, KJ Goodlet, MD Nailor… - American Journal of …, 2018 - Elsevier
Following a year of valganciclovir prophylaxis, a lung transplant recipient developed
cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by …

Cytomegalovirus infection in organ transplant recipients

PL Hibberd, DR Snydman - Infectious disease clinics of North America, 1995 - Elsevier
Cytomegalovirus (CMV) continues to be responsible for a substantial fraction of the
morbidity and mortality that follows organ transplantation. The three major consequences of …

Impact of cytomegalovirus infection on organ transplant recipients

RH Rubin - Reviews of infectious diseases, 1990 - academic.oup.com
Cytomegalovirus (CMV) is the single most important infectious agent affecting recipients of
organ transplants, with at least two-thirds of these patients having CMV infection 1–4 months …